<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-160552" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Temazepam</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Fluyau</surname>
            <given-names>Dimy</given-names>
          </name>
          <aff>University of Florida</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Ponnarasu</surname>
            <given-names>Subitchan</given-names>
          </name>
          <aff>Ramaiah Medical College &#x00026; Hospitals, Bangalore, India</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Patel</surname>
            <given-names>Preeti</given-names>
          </name>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Dimy Fluyau declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Subitchan Ponnarasu declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Preeti Patel declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>11</day>
          <month>1</month>
          <year>2024</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-160552.s1" sec-type="Indications">
        <title>Indications</title>
        <p content-type="pubmed-excerpt">Temazepam, a member of the benzodiazepine class, is identified by its chemical name, 7-chloro-1,3-dihydro-3-hydroxy-1-methyl-5-phenyl-2H-1,4-benzodiazepin-2-one, and is synthesized from the intermediate product of oxazepam.<xref ref-type="bibr" rid="article-160552.r1">[1]</xref><xref ref-type="bibr" rid="article-160552.r2">[2]</xref>&#x000a0;Temazepam is classified as a positive allosteric modulator of gamma-aminobutyric acid (GABA-PAM). The pharmacological effects of the drug are attained by modulating GABA, leading to an increase in GABA's inhibitory effects on neuronal excitability.<xref ref-type="bibr" rid="article-160552.r3">[3]</xref>&#x000a0;</p>
        <p>Temazepam was introduced to the market in 1964. However, it was during the 1980s that the drug experienced a significant surge in popularity, emerging as one of the most frequently prescribed medications for recreational use in various European countries.<xref ref-type="bibr" rid="article-160552.r4">[4]</xref></p>
        <p>Temazepam is known by various street names, including Eggs, Green Eggs, Jellies, Norries, Rugby Balls, Tems, and Mozzies. Temazepam has a high potential risk of abuse, misuse, addiction, physical dependency, and withdrawal responses, consistent with the risk profile associated with all benzodiazepines.<xref ref-type="bibr" rid="article-160552.r5">[5]</xref> The Drug Enforcement Administration (DEA) and the U.S. Food and Drug Administration (FDA) enforce the classification of temazepam as a Schedule IV controlled substance in the United States.<xref ref-type="bibr" rid="article-160552.r6">[6]</xref></p>
        <p>
<bold>FDA-Approved Indications</bold>
</p>
        <p>Although temazepam was approved for use in the United States in 1981, it remains a popular drug, with over 2 million prescriptions filled annually.<xref ref-type="bibr" rid="article-160552.r7">[7]</xref>&#x000a0;Temazepam is indicated for the short-term management of insomnia, with instructions typically recommending its use for 7 to 10 days. The conclusive assessment of sleep latency is conducted after the completion of the treatment regimen.<xref ref-type="bibr" rid="article-160552.r8">[8]</xref></p>
        <p>Temazepam is used to treat insomnia and other sleep-related issues, including frequent awakenings during the night or early in the morning. Research indicates that temazepam is effective in maintaining sleep, although its impact on the delay in sleep onset is relatively modest.<xref ref-type="bibr" rid="article-160552.r9">[9]</xref>&#x000a0;Further research indicates that temazepam significantly affects persistent sleep latency within the 15- to 30-mg range, resulting in an average reduction of approximately 25% to 50%. The effects of temazepam on the structure of sleep are minimal, displaying the typical benzodiazepine effect of decreasing stages 3 and 4. However, this outcome has shown inconsistencies and may be sensitive to dosage and duration. Non-rapid eye movement (REM) sleep is typically unaffected.<xref ref-type="bibr" rid="article-160552.r9">[9]</xref><xref ref-type="bibr" rid="article-160552.r10">[10]</xref></p>
        <p>
<bold>Off-Label Uses</bold>
</p>
        <p>Studies have demonstrated that temazepam can be beneficial in addressing sleep disruptions associated with jet lag. Consideration may also be given to the use of temazepam in short-term shift work and acute stress situations.<xref ref-type="bibr" rid="article-160552.r11">[11]</xref><xref ref-type="bibr" rid="article-160552.r12">[12]</xref><xref ref-type="bibr" rid="article-160552.r13">[13]</xref> Temazepam may also be regarded as a potential remedy for "acute mountain sickness"&#x02014;a condition often experienced by mountain climbers. The medication is well-tolerated and does not adversely affect performance on the following day when used at high altitudes to mitigate periodic breathing.<xref ref-type="bibr" rid="article-160552.r14">[14]</xref>&#x000a0;</p>
        <p>On an interim basis, usually for 7 to 10 days, temazepam is prescribed to address panic and anxiety disorders.<xref ref-type="bibr" rid="article-160552.r15">[15]</xref> In addition to its anticonvulsant effects, temazepam is capable of relaxing skeletal muscles. Temazepam has been utilized in treating nocturnal myoclonus and as a premedication before minimally invasive surgery.<xref ref-type="bibr" rid="article-160552.r16">[16]</xref><xref ref-type="bibr" rid="article-160552.r17">[17]</xref>&#x000a0;Furthermore, it is essential to exercise caution in any off-label use of temazepam, considering box warnings and the potential for misuse.</p>
      </sec>
      <sec id="article-160552.s2" sec-type="Mechanism of Action">
        <title>Mechanism of Action</title>
        <p>Temazepam induces central nervous system (CNS) depression by affecting the limbic, thalamic, and hypothalamic regions.<xref ref-type="bibr" rid="article-160552.r7">[7]</xref>&#x000a0;Temazepam exerts its pharmacological effects, including drowsiness, hypnosis, skeletal muscle relaxation, anticonvulsant action, and anxiolysis, by binding to benzodiazepine receptors. These receptors constitute several GABA-A receptor subtypes, with a particular affinity for &#x003b1;1 subunits.<xref ref-type="bibr" rid="article-160552.r18">[18]</xref>&#x000a0;</p>
        <p>Benzodiazepines increase chloride ion influx, leading to neuronal membrane hyperpolarization and reduced neuronal excitability. The hyperpolarized state of the cell membrane impedes further excitation of the associated neurons, as binding enhances the aforementioned chloride ion conduction, manifested through an increased frequency of the chloride channel opening.<xref ref-type="bibr" rid="article-160552.r7">[7]</xref>&#x000a0;In a study on rats, temazepam was observed to modulate the hypothalamic-pituitary-adrenal (HPA) axis by altering GABA-A receptors and elevating vasopressin levels in the hypothalamus.<xref ref-type="bibr" rid="article-160552.r19">[19]</xref>&#x000a0;</p>
        <p>Temazepam administration induces a dose-dependent increase in vasopressin release, while levels of plasma neuropeptides remain unchanged in response to stress. As a result, temazepam demonstrates a dual mechanism of action in suppressing HPA axis activity&#x02014;directly through the modulation of GABA-A receptors and indirectly by elevating vasopressin concentrations within the hypothalamus.&#x000a0;Temazepam was associated with decreased systolic blood pressure and increased heart rate when administered in the morning.<xref ref-type="bibr" rid="article-160552.r20">[20]</xref>&#x000a0;Benzodiazepines,&#x000a0;including temazepam, increase the frequency of chloride channel opening, whereas barbiturates prolong the opening duration of chloride channels.<xref ref-type="bibr" rid="article-160552.r21">[21]</xref><xref ref-type="bibr" rid="article-160552.r22">[22]</xref></p>
        <p>
<bold>Pharmacokinetics</bold>
</p>
        <p><bold>Absorption:</bold> Temazepam is efficiently absorbed after oral administration, with a minimal first-pass metabolism of only 8%. The time to reach peak plasma concentration (Tmax) varies between 1.2 and 1.6 hours, with an average Tmax of 1.5 hours after administration.<xref ref-type="bibr" rid="article-160552.r23">[23]</xref></p>
        <p><bold>Distribution:</bold> Temazepam has a recorded mean volume of distribution of 1.40 L/kg, which does not vary with age or sex.<xref ref-type="bibr" rid="article-160552.r24">[24]</xref><xref ref-type="bibr" rid="article-160552.r25">[25]</xref>&#x000a0;Temazepam exhibits a high plasma protein binding capacity, typically around 96%.<xref ref-type="bibr" rid="article-160552.r26">[26]</xref></p>
        <p><bold>Metabolism:</bold> Temazepam is eliminated from the body through direct glucuronide conjugation, with the resulting conjugate, temazepam glucuronide, being excreted in the urine.<xref ref-type="bibr" rid="article-160552.r27">[27]</xref>&#x000a0;A significantly smaller proportion undergoes parallel oxidation, leading to the formation of oxazepam. Oxazepam is then conjugated to oxazepam glucuronide, which is ultimately eliminated in the urine.<xref ref-type="bibr" rid="article-160552.r28">[28]</xref>&#x000a0;Individuals diagnosed with cirrhosis may encounter a prolonged onset of temazepam's hypnotic properties. However, the drug's clearance and accumulation profiles are identical to those of healthy individuals of similar sex and age.<xref ref-type="bibr" rid="article-160552.r29">[29]</xref></p>
        <p>Most unmodified temazepam is promptly converted to glucuronide and is subsequently excreted in the urine, highlighting the pivotal role of the liver in the drug's metabolism. Temazepam's O-conjugate emerges as the most abundant metabolite in the body.<xref ref-type="bibr" rid="article-160552.r30">[30]</xref>&#x000a0;There is no evidence to suggest that the glucuronides of temazepam have any activity on the CNS.&#x000a0;Temazepam is hypothesized to lack interactions with CYP450 and primarily metabolizes through phase II conjugation reactions.<xref ref-type="bibr" rid="article-160552.r31">[31]</xref>&#x000a0;Although the mechanism underlying this occurrence remains unknown, several hypotheses have been proposed. The symptoms of liver injury could be masked if there is a substantial reserve of glucuronyl transferase intra- or extra-hepatically. Glucuronyl transferase may be less susceptible to liver damage. In addition, due to the high affinity of glucuronyl transferases for ATP, glucuronidation is protected in low-ATP environments, albeit potentially at the expense of processes mediated by other enzymes.<xref ref-type="bibr" rid="article-160552.r32">[32]</xref></p>
        <p><bold>Elimination:</bold> Research on temazepam clearance has revealed values of 1.03 mL/min/kg for total temazepam and 31 mL/min/kg for unbound temazepam. Notably, 80% to 90% of a single dose of temazepam is excreted in the urine, primarily as the O-conjugate metabolite. In contrast, only 3% to&#x000a0;13% is eliminated in the feces. <italic toggle="yes">N</italic>-desmethyl temazepam and unmodified temazepam account for less than 2% of the dose eliminated in the urine.<xref ref-type="bibr" rid="article-160552.r2">[2]</xref>&#x000a0;Temazepam displays a biphasic elimination pattern. In cases of drugs exhibiting such a pattern, the clinically relevant half-life aligns with the second phase, commonly referred to as the terminal half-life.<xref ref-type="bibr" rid="article-160552.r33">[33]</xref>&#x000a0;According to the FDA-approved product labeling, the terminal half-life of temazepam ranges from 3.5 to 18.4 hours, with an average of 8.8 hours.<xref ref-type="bibr" rid="article-160552.r34">[34]</xref>&#x000a0;The half-life can be prolonged in older adults and individuals with preexisting medical conditions.</p>
      </sec>
      <sec id="article-160552.s3" sec-type="Administration">
        <title>Administration</title>
        <p>
<bold>Available Dosage Forms and Strengths</bold>
</p>
        <p>Temazepam is a white,&#x000a0;crystalline drug with a powdery consistency and a moderate degree of solubility in water, whereas alcohol permits only a limited solubility for temazepam.<xref ref-type="bibr" rid="article-160552.r35">[35]</xref>&#x000a0;Temazepam is available in liquid, gel, or powder forms and packaged in either hard or soft capsules.<xref ref-type="bibr" rid="article-160552.r2">[2]</xref></p>
        <p>The available dosage strengths of temazepam include 7.5 mg, 10 mg, 15 mg, 20 mg, and 30 mg.<xref ref-type="bibr" rid="article-160552.r35">[35]</xref><xref ref-type="bibr" rid="article-160552.r10">[10]</xref><xref ref-type="bibr" rid="article-160552.r36">[36]</xref> United States Pharmacopeia (USP) capsules are formulated in 7.5 mg, 15 mg, 22.5 mg, and 30 mg for oral administration.</p>
        <p>
<bold>Adult Dosage</bold>
</p>
        <p>According to the task force of the American Academy of Sleep Medicine, there is limited evidence supporting the use of temazepam for sleep onset and sleep maintenance insomnia in adults when compared to no treatment. The recommended dose of temazepam is 15 mg, with the option to increase to 30 mg based on the therapeutic response. Polysomnography results indicated that the temazepam group experienced a significantly shorter sleep latency. Subjective sleep latency was also reduced, and total sleep time increased based on polysomnography&#x000a0;analysis. According to the subjective assessment, the use of temazepam resulted in an increase in the total duration of sleep. These findings suggest notable improvements in sleep latency and total sleep time attributed to temazepam use, as observed through both objective and subjective measurements.<xref ref-type="bibr" rid="article-160552.r37">[37]</xref></p>
        <p>
<bold>Specific Patient Populations</bold>
</p>
        <p><bold>Renal impairment:&#x000a0;</bold>The product labeling does not provide instructions for adjusting the temazepam dosage for renal impairment.</p>
        <p><bold>Hepatic impairment:&#x000a0;</bold>The product labeling does not provide instructions for adjusting the temazepam dosage for renal impairment.</p>
        <p><bold>Pregnancy considerations:&#x000a0;</bold>Temazepam should be avoided by pregnant women, as it is classified as an FDA pregnancy category X drug. If the medication is used during pregnancy or if the patient becomes pregnant while taking it, the potential fetal risks should be thoroughly discussed with the patient. When administered to a pregnant woman, temazepam can cause fetal harm. Damen et al reported a potentially fatal outcome when a mother of a newborn child took 20 mg of temazepam. The delivery was rapid, and the newborn exhibited signs of being blue, weak, and unresponsive.<xref ref-type="bibr" rid="article-160552.r38">[38]</xref>&#x000a0;</p>
        <p>Elevated rates of embryonic resorptions were observed at 30 and 120 mg/kg dosages, whereas a higher incidence of rudimentary ribs was noted at 240 mg/kg or above dosages. Exencephaly and fusion or asymmetry of the ribs were also observed, with no discernible correlation to dosage.<xref ref-type="bibr" rid="article-160552.r39">[39]</xref> In an animal study, the administration of oral dosages of temazepam at 60 mg/kg/d led to an observed increase in newborn mortality rates. It is crucial to closely monitor newborns exposed to temazepam during prenatal development for potential complications, including feeding difficulties, respiratory depression, sedation, and withdrawal symptoms. Floppy infant syndrome is associated with benzodiazepines used during pregnancy and is characterized by hypotonia, lethargy, and respiratory depression.<xref ref-type="bibr" rid="article-160552.r40">[40]</xref></p>
        <p><bold>Breastfeeding considerations</bold>: Due to the low levels of temazepam found in breastmilk, the amounts consumed by the infant are minimal and are not expected to cause any adverse effects. Taking the bedtime dose after the infant's last feeding of the day may decrease the dose received by an infant who sleeps through the night. Monitoring the infant for signs of drowsiness, poor weight gain, and reduced feeding is recommended.<xref ref-type="bibr" rid="article-160552.r4">[4]</xref></p>
        <p><bold>Pediatric patients: </bold>The safety and effectiveness of temazepam in pediatric patients have not been established.</p>
        <p><bold>Older patients: </bold>The American Geriatrics Society Beers Criteria (2023) emphasizes the avoidance of benzodiazepines, including temazepam, due to their association with increased risks of delirium, cognitive decline, falls, fractures, and motor vehicle accidents in older individuals. However, the American Geriatric Society acknowledges that benzodiazepines may be deemed appropriate for specific conditions, such as seizure disorders, periprocedural anesthesia, benzodiazepine withdrawal, severe generalized anxiety disorder, alcohol withdrawal, and REM sleep disorder. As previously explained, due to the heightened risk of oversedation, dizziness, disorientation, ataxia, and falls associated with higher doses of benzodiazepines in older patients, it is advisable to initiate treatment with a lower dosage of temazepam at 7.5 mg for individuals 65 and older.<xref ref-type="bibr" rid="article-160552.r2">[2]</xref><xref ref-type="bibr" rid="article-160552.r41">[41]</xref></p>
      </sec>
      <sec id="article-160552.s4" sec-type="Adverse Effects">
        <title>Adverse Effects</title>
        <p>
<bold>Adverse Drug Reactions</bold>
</p>
        <p>A post-marketing surveillance study was conducted to investigate the adverse effects of temazepam. The study included a sample of 10,057 patients who were administered a 40- to 60-mg dosage for 2 weeks and another group of 8043 patients who received the exact dosage for 3 months. The observed prevalence rate of hangovers in these patient groups was 7%. Furthermore, numerous adverse effects have been documented across various organ systems. Complaints about the cardiovascular system included palpitations, whereas gastrointestinal symptoms included xerostomia, dysgeusia, emesis, diarrhea, epigastric discomfort, and constipation. Neurological symptoms included headache, disorientation, drowsiness, dizziness, giddiness, unsteadiness, anterograde amnesia, and paresthesia. Commonly mentioned psychiatric symptoms included vivid dreams, nightmares, and depression. Temazepam can adversely impact social and mental health and cause violent outbursts at home and in public and psychological disorders, including paranoia and other irrational behaviors.<xref ref-type="bibr" rid="article-160552.r42">[42]</xref><xref ref-type="bibr" rid="article-160552.r43">[43]</xref></p>
        <p>
<bold>Drug-Drug Interactions</bold>
</p>
        <p>The concomitant administration of temazepam with opioid prescriptions, alcohol, or other&#x000a0;CNS depressants can lead to significant drowsiness, respiratory depression, unconsciousness, and even fatality. Lingering effects on psychomotor and cognitive abilities may result in impaired driving ability and potentially higher risks of falling and hip fractures. Furthermore, the activity of temazepam can be disrupted by the concurrent use of barbiturates, nonselective monoamine oxidase inhibitors, phenothiazines, antipsychotics, skeletal muscle relaxants, and antihistamines.<xref ref-type="bibr" rid="article-160552.r6">[6]</xref><xref ref-type="bibr" rid="article-160552.r44">[44]</xref><xref ref-type="bibr" rid="article-160552.r45">[45]</xref></p>
        <p>In relation to alcohol, a study compared blood concentrations of 80 to 100 mg/100 mL of ethanol with those of 20 mg and 30 mg of temazepam in terms of psychomotor speed, accuracy, and long-term memory. Ethanol and 30 mg of temazepam exhibited similar effects on information processing capacity and long-term memory formation. However, ethanol had a significantly distinct impact on psychomotor performance compared to temazepam, leading to faster but more error-prone behavior.<xref ref-type="bibr" rid="article-160552.r46">[46]</xref></p>
      </sec>
      <sec id="article-160552.s5" sec-type="Contraindications">
        <title>Contraindications</title>
        <p>Temazepam is contraindicated in pregnancy, as it is classified as an FDA pregnancy category X drug.<xref ref-type="bibr" rid="article-160552.r34">[34]</xref></p>
        <p>
<bold>Box Warnings</bold>
</p>
        <p>Similar to all other oral benzodiazepines, temazepam&#x000a0;carries a boxed warning on the product label emphasizing the risks of severe sedation and potentially fatal respiratory depression when combined with opioids.<xref ref-type="bibr" rid="article-160552.r47">[47]</xref></p>
        <p>The potential for abuse, misuse, and addiction associated with temazepam increases the risk of overdose or fatality. Before prescribing temazepam and throughout treatment, the risk of abuse, misuse, and addiction in each patient should be evaluated. Intravenous administration is the main method of abuse for temazepam capsules.<xref ref-type="bibr" rid="article-160552.r48">[48]</xref>&#x000a0;The adverse effects of temazepam intravenously include venous and arterial thrombosis, compartment syndrome, gangrene, and rhabdomyolysis.<xref ref-type="bibr" rid="article-160552.r49">[49]</xref><xref ref-type="bibr" rid="article-160552.r50">[50]</xref>&#x000a0;</p>
        <p>Temazepam, often combined with buprenorphine in a "cocktail," may increase the risk of overdose.<xref ref-type="bibr" rid="article-160552.r51">[51]</xref>&#x000a0;Individuals who use temazepam are more likely to share needles, putting themselves and others at risk of contracting hepatitis and HIV. Consequently, many manufacturers have transitioned from producing liquid-filled capsules to manufacturing tablets and gel. However, users discovered that the gel could be melted with a hot needle, making it easier&#x000a0;to inject.<xref ref-type="bibr" rid="article-160552.r50">[50]</xref><xref ref-type="bibr" rid="article-160552.r42">[42]</xref></p>
        <p>Developing a tolerance to temazepam is possible, especially if it is used for a moderate-to-long period. Symptoms and signs of temazepam withdrawal may include agitation, irritability, dysphoria, depersonalization, twitching, muscle cramps and discomfort, weakness, ataxia, headache, hypersensitivity to lights and other stimuli, nausea, sweating, and vomiting. Acute delirium, characterized by impaired attention and cognition, may be an ominous sign of temazepam withdrawal. Disruptions in sleep and mood have been identified as signs of withdrawal tolerance.</p>
        <p>The mechanism of discontinuation from temazepam is the same as that of any other benzodiazepine. Abrupt discontinuation of continuous treatment with benzodiazepines may lead to withdrawal or rebound syndrome. In contrast to a sole increase in benzodiazepine binding sites, an augmentation in the number of binding sites for both benzodiazepines and chloride-channel ligands suggests that the available number of GABA-A receptor complexes is heightened following benzodiazepine discontinuation.<xref ref-type="bibr" rid="article-160552.r52">[52]</xref> Sleep lab studies have confirmed rebound insomnia following the sudden cessation of short-term, therapeutic benzodiazepine use as a hypnotic or anxiolytic. Temazepam induces rebound insomnia after abrupt discontinuation, which can contribute to relapse and continued drug use.<xref ref-type="bibr" rid="article-160552.r53">[53]</xref><xref ref-type="bibr" rid="article-160552.r54">[54]</xref></p>
        <p>
<bold>Precautions</bold>
</p>
        <p>The use of temazepam should be minimized or entirely avoided in individuals with severe motor coordination impairment, acute intoxication with alcohol, opioids, or other psychoactive substances, sleep apnea, myasthenia gravis, acute narrow-angle glaucoma, clinically significant major depressive disorder with suicidal ideation, renal and hepatic insufficiency, hypersensitivity, or allergy to any benzodiazepines.<xref ref-type="bibr" rid="article-160552.r55">[55]</xref><xref ref-type="bibr" rid="article-160552.r56">[56]</xref></p>
      </sec>
      <sec id="article-160552.s6" sec-type="Monitoring">
        <title>Monitoring</title>
        <p>Healthcare professionals, including physicians, nurses, and pharmacists, must have a comprehensive understanding of the advantages and drawbacks associated with using temazepam as a therapeutic intervention for insomnia. Patients should only use temazepam, a benzodiazepine, for short-term sleep management, and this limitation should be communicated to them. In addition, patients should be aware that temazepam will be gradually tapered over a specific period to mitigate the risk of precipitating an acute withdrawal syndrome, which can lead to severe medical and neuropsychiatric complications.</p>
        <p>Patients must also be educated about temazepam alternatives. Instead of relying on a one-size-fits-all strategy, promoting lifestyle changes and creating an environment that encourages physical activity and healthy sleep habits can help address sleep disorders and improve sleep quality. A multiapproach should be considered to address sleep problems effectively and choose the optimal treatment option. Integrating the patient, family, pharmacy, substance abuse counselor, addiction specialist, sleep specialist, and other healthcare providers is essential for creating a healthier path in treating sleep disorders. Thus, a balanced approach involving all relevant parties should be weighed with the patient's well-being in mind.</p>
        <p>Healthcare practitioners should consistently monitor their patients for temazepam misuse and provide education about the potential risks. Prescription drug monitoring programs can assist in monitoring potential misuse.<xref ref-type="bibr" rid="article-160552.r57">[57]</xref> In a study involving older veterans with insomnia, approximately half were found to have undiagnosed sleep-disordered breathing.<xref ref-type="bibr" rid="article-160552.r58">[58]</xref> Polysomnography should be considered on an individual basis when sleep-related breathing disorders, such as obstructive or central sleep apnea, nocturnal seizures, periodic limb movement disorder, REM sleep disorder, and narcolepsy, are suspected.<xref ref-type="bibr" rid="article-160552.r59">[59]</xref>&#x000a0;Screening for underlying anxiety and depression should also be considered in patients in case of inadequate therapeutic response.<xref ref-type="bibr" rid="article-160552.r60">[60]</xref>&#x000a0;Clinicians can assess disease severity using tools such as the Insomnia Severity Index (ISI).<xref ref-type="bibr" rid="article-160552.r61">[61]</xref><xref ref-type="bibr" rid="article-160552.r62">[62]</xref></p>
      </sec>
      <sec id="article-160552.s7" sec-type="Toxicity">
        <title>Toxicity</title>
        <p>
<bold>Signs and Symptoms of Overdose</bold>
</p>
        <p>Deaths from self-poisoning with temazepam alone or in combination with other substances were shown to be more common than with any other benzodiazepines except flurazepam, which had the highest mortality rate per million prescriptions. It has been claimed that disulfiram can hasten temazepam's toxicity by heightening the depression of the CNS.<xref ref-type="bibr" rid="article-160552.r2">[2]</xref>&#x000a0;Acute overdosing on temazepam, like other benzodiazepines, manifests in sleepiness, confusion, and coma.</p>
        <p>Moreover, it has been observed that overdoses of temazepam and zopiclone/zolpidem are more prone to fatalities compared to diazepam overdoses. Temazepam was found to be 10 times more hazardous than diazepam, whereas zopiclone, eszopiclone, zaleplon, and zolpidem (Z-drugs) were each just 9 times more toxic than diazepam.<xref ref-type="bibr" rid="article-160552.r45">[45]</xref> Temazepam has been associated with higher toxicity than other benzodiazepines in studies of intentional self-poisoning in a large national sample of veterans prescribed opioid analgesics.<xref ref-type="bibr" rid="article-160552.r63">[63]</xref>&#x000a0;However, temazepam was linked to a lower overdose mortality rate than clonazepam.<xref ref-type="bibr" rid="article-160552.r64">[64]</xref>&#x000a0;The oral LD50 of temazepam was 1963 mg/kg in mice, 1833 mg/kg in rats, and &#x0003e;2400 mg/kg in rabbits.</p>
        <p>
<bold>Management of Overdose</bold>
</p>
        <p>Temazepam overdose therapy involves supportive care, including airway, breathing, and circulatory examinations. Complex cases may require intensive care unit admission. The Poison Control Center can be contacted for assistance in complicated poisoning cases.<xref ref-type="bibr" rid="article-160552.r65">[65]</xref>&#x000a0;The sedative effects of temazepam can be counteracted by flumazenil&#x02014;a nonspecific competitive antagonist at the benzodiazepine receptor.<xref ref-type="bibr" rid="article-160552.r66">[66]</xref></p>
      </sec>
      <sec id="article-160552.s8" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>The sleep-wake cycle is a multifaceted phenomenon that involves several physiological and behavioral fluctuations.<xref ref-type="bibr" rid="article-160552.r67">[67]</xref><xref ref-type="bibr" rid="article-160552.r68">[68]</xref> Epigenetic occurrences play a significant role in regulating sleep homeostasis and circadian rhythms, contributing to the understanding of the pathogenesis of sleep disorders such as sleep apnea, insomnia, sleep deprivation, and associated comorbidities.<xref ref-type="bibr" rid="article-160552.r69">[69]</xref><xref ref-type="bibr" rid="article-160552.r70">[70]</xref>&#x000a0;Sleep dysfunction, which includes insufficient sleep length and poor sleep quality, has been associated with various negative health outcomes, including hypertension, diabetes, cancer, anxiety, and major depressive disorder.<xref ref-type="bibr" rid="article-160552.r71">[71]</xref><xref ref-type="bibr" rid="article-160552.r72">[72]</xref><xref ref-type="bibr" rid="article-160552.r73">[73]</xref> Sleepiness and exhaustion resulting from insufficient sleep during wakefulness can impair performance and productivity, leading to absenteeism and an increased risk of work-related accidents.<xref ref-type="bibr" rid="article-160552.r74">[74]</xref><xref ref-type="bibr" rid="article-160552.r75">[75]</xref></p>
        <p>Quality of life is multifaceted, consisting of various physical, psychological, and social dimensions. Research has demonstrated that both lower sleep quantity and poor sleep quality have damaging effects on these dimensions.<xref ref-type="bibr" rid="article-160552.r76">[76]</xref><xref ref-type="bibr" rid="article-160552.r77">[77]</xref>&#x000a0;As noted above, insomnia frequently coexists with certain primary sleep disorders such as restless legs syndrome, periodic limb movement disorders, and sleep-related breathing disorders, which require referral to sleep medicine specialists.<xref ref-type="bibr" rid="article-160552.r78">[78]</xref>&#x000a0;Medical disorders leading to insomnia, such as hyperthyroidism, should be ruled out.<xref ref-type="bibr" rid="article-160552.r79">[79]</xref>&#x000a0;The decision to initiate temazepam should be carefully evaluated, considering medical and neuropsychiatric issues, as well as the potential to improve overall quality of life.</p>
        <p>The use of benzodiazepines as pharmacological therapies for treating sleep-related disorders has received a lot of attention lately. Temazepam, a benzodiazepine, belongs to the same category and carries similar risks for patients, such as overdose, respiratory depression, falls, abuse, misuse, and addiction. Therefore, physicians, advanced practitioners, nurses, pharmacists, and other health professionals must be well-versed and knowledgeable of the mechanism of action of temazepam, adverse effects, and strategies to mitigate complications that can lead to adverse outcomes.&#x000a0;Pharmacists should conduct medication reconciliation and verify that opioids have not been co-prescribed with temazepam. Nurses should monitor the response to therapy and alert the team about adherence and potential signs of misuse.</p>
        <p>Persistent insomnia that does not respond to temazepam necessitates referral to a psychiatrist. Patients should receive counseling on the appropriate use of temazepam and be closely monitored for indications and symptoms of abuse, misuse, and drug use disorder. Early treatment should be initiated for individuals with a high suspicion that they are developing a substance use issue, and they should be referred to addiction medicine specialists. Severe poisoning may require admission to the Medical Intensive Care Unit (MICU) under the supervision of critical care physicians.</p>
        <p>The sudden cessation of temazepam can also induce severe and possibly life-threatening medical problems. Before initiating temazepam for a patient, a comprehensive assessment should consider its advantages, disadvantages, and alternative options carefully. The physician-patient connection, the involvement of the patient's family, and the support system should be considered while making such a decision. The incorporation of the concepts of beneficence and autonomy is crucial when making such a decision. An interprofessional team approach involving clinicians (MDs, DOs, NPs, and PAs), specialists, nurses, and pharmacists is essential for optimal use of temazepam for insomnia.</p>
      </sec>
      <sec id="article-160552.s9">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=160552&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=160552">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/160552/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=160552">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-160552.s10">
        <title>References</title>
        <ref id="article-160552.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mitler</surname>
                <given-names>MM</given-names>
              </name>
            </person-group>
            <article-title>Evaluation of temazepam as a hypnotic.</article-title>
            <source>Pharmacotherapy</source>
            <year>1981</year>
            <season>Jul-Aug</season>
            <volume>1</volume>
            <issue>1</issue>
            <fpage>3</fpage>
            <page-range>3-13</page-range>
            <pub-id pub-id-type="pmid">6152815</pub-id>
          </element-citation>
        </ref>
        <ref id="article-160552.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <article-title>Temazepam.</article-title>
            <source>IARC Monogr Eval Carcinog Risks Hum</source>
            <year>1996</year>
            <volume>66</volume>
            <fpage>161</fpage>
            <page-range>161-73</page-range>
            <pub-id pub-id-type="pmid">9097124</pub-id>
          </element-citation>
        </ref>
        <ref id="article-160552.r3">
          <label>3</label>
          <element-citation publication-type="book">
            <chapter-title>Temazepam</chapter-title>
            <source>LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]</source>
            <publisher-name>National Institute of Diabetes and Digestive and Kidney Diseases</publisher-name>
            <publisher-loc>Bethesda (MD)</publisher-loc>
            <year>2023</year>
            <month>6</month>
            <day>22</day>
            <pub-id pub-id-type="pmid">31643873</pub-id>
          </element-citation>
        </ref>
        <ref id="article-160552.r4">
          <label>4</label>
          <element-citation publication-type="book">
            <chapter-title>Temazepam</chapter-title>
            <source>Drugs and Lactation Database (LactMed&#x000ae;) [Internet]</source>
            <publisher-name>National Institute of Child Health and Human Development</publisher-name>
            <publisher-loc>Bethesda (MD)</publisher-loc>
            <year>2023</year>
            <month>2</month>
            <day>15</day>
            <pub-id pub-id-type="pmid">30000315</pub-id>
          </element-citation>
        </ref>
        <ref id="article-160552.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ralston</surname>
                <given-names>GE</given-names>
              </name>
              <name>
                <surname>Taylor</surname>
                <given-names>JA</given-names>
              </name>
            </person-group>
            <article-title>Temazepam abuse.</article-title>
            <source>Addiction</source>
            <year>1993</year>
            <month>Mar</month>
            <volume>88</volume>
            <issue>3</issue>
            <fpage>423</fpage>
            <pub-id pub-id-type="pmid">8461860</pub-id>
          </element-citation>
        </ref>
        <ref id="article-160552.r6">
          <label>6</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Preuss</surname>
                <given-names>CV</given-names>
              </name>
              <name>
                <surname>Kalava</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>King</surname>
                <given-names>KC</given-names>
              </name>
            </person-group>
            <chapter-title>Prescription of Controlled Substances: Benefits and Risks</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2023</year>
            <month>4</month>
            <day>29</day>
            <pub-id pub-id-type="pmid">30726003</pub-id>
          </element-citation>
        </ref>
        <ref id="article-160552.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Fraschini</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Stankov</surname>
                <given-names>B</given-names>
              </name>
            </person-group>
            <article-title>Temazepam: pharmacological profile of a benzodiazepine and new trends in its clinical application.</article-title>
            <source>Pharmacol Res</source>
            <year>1993</year>
            <season>Feb-Mar</season>
            <volume>27</volume>
            <issue>2</issue>
            <fpage>97</fpage>
            <page-range>97-113</page-range>
            <pub-id pub-id-type="pmid">8474963</pub-id>
          </element-citation>
        </ref>
        <ref id="article-160552.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <article-title>Temazepam for insomnia?</article-title>
            <source>Drug Ther Bull</source>
            <year>1978</year>
            <month>Mar</month>
            <day>17</day>
            <volume>16</volume>
            <issue>6</issue>
            <fpage>21</fpage>
            <page-range>21-2</page-range>
            <pub-id pub-id-type="pmid">631020</pub-id>
          </element-citation>
        </ref>
        <ref id="article-160552.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bixler</surname>
                <given-names>EO</given-names>
              </name>
              <name>
                <surname>Kales</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Soldatos</surname>
                <given-names>CR</given-names>
              </name>
              <name>
                <surname>Scharf</surname>
                <given-names>MB</given-names>
              </name>
              <name>
                <surname>Kales</surname>
                <given-names>JD</given-names>
              </name>
            </person-group>
            <article-title>Effectiveness of temazepam with short-intermediate-, and long-term use: sleep laboratory evaluation.</article-title>
            <source>J Clin Pharmacol</source>
            <year>1978</year>
            <season>Feb-Mar</season>
            <volume>18</volume>
            <issue>2-3</issue>
            <fpage>110</fpage>
            <page-range>110-8</page-range>
            <pub-id pub-id-type="pmid">342551</pub-id>
          </element-citation>
        </ref>
        <ref id="article-160552.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mitler</surname>
                <given-names>MM</given-names>
              </name>
              <name>
                <surname>Carskadon</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Phillips</surname>
                <given-names>RL</given-names>
              </name>
              <name>
                <surname>Sterling</surname>
                <given-names>WR</given-names>
              </name>
              <name>
                <surname>Zarcone</surname>
                <given-names>VP</given-names>
              </name>
              <name>
                <surname>Spiegel</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Guilleminault</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Dement</surname>
                <given-names>WC</given-names>
              </name>
            </person-group>
            <article-title>Hypnotic efficacy of temazepam: a long-term sleep laboratory evaluation.</article-title>
            <source>Br J Clin Pharmacol</source>
            <year>1979</year>
            <volume>8</volume>
            <issue>1</issue>
            <fpage>63S</fpage>
            <page-range>63S-68S</page-range>
            <pub-id pub-id-type="pmid">41543</pub-id>
          </element-citation>
        </ref>
        <ref id="article-160552.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Morgenthaler</surname>
                <given-names>TI</given-names>
              </name>
              <name>
                <surname>Lee-Chiong</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Alessi</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Friedman</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Aurora</surname>
                <given-names>RN</given-names>
              </name>
              <name>
                <surname>Boehlecke</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Brown</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Chesson</surname>
                <given-names>AL</given-names>
              </name>
              <name>
                <surname>Kapur</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Maganti</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Owens</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Pancer</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Swick</surname>
                <given-names>TJ</given-names>
              </name>
              <name>
                <surname>Zak</surname>
                <given-names>R</given-names>
              </name>
              <collab>Standards of Practice Committee of the American Academy of Sleep Medicine</collab>
            </person-group>
            <article-title>Practice parameters for the clinical evaluation and treatment of circadian rhythm sleep disorders. An American Academy of Sleep Medicine report.</article-title>
            <source>Sleep</source>
            <year>2007</year>
            <month>Nov</month>
            <volume>30</volume>
            <issue>11</issue>
            <fpage>1445</fpage>
            <page-range>1445-59</page-range>
            <pub-id pub-id-type="pmid">18041479</pub-id>
          </element-citation>
        </ref>
        <ref id="article-160552.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nicholson</surname>
                <given-names>AN</given-names>
              </name>
              <name>
                <surname>Stone</surname>
                <given-names>BM</given-names>
              </name>
            </person-group>
            <article-title>Hypnotics and transient insomnia.</article-title>
            <source>Acta Psychiatr Scand Suppl</source>
            <year>1986</year>
            <volume>332</volume>
            <fpage>55</fpage>
            <page-range>55-9</page-range>
            <pub-id pub-id-type="pmid">2883829</pub-id>
          </element-citation>
        </ref>
        <ref id="article-160552.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Arendt</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Approaches to the Pharmacological Management of Jet Lag.</article-title>
            <source>Drugs</source>
            <year>2018</year>
            <month>Sep</month>
            <volume>78</volume>
            <issue>14</issue>
            <fpage>1419</fpage>
            <page-range>1419-1431</page-range>
            <pub-id pub-id-type="pmid">30167980</pub-id>
          </element-citation>
        </ref>
        <ref id="article-160552.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nickol</surname>
                <given-names>AH</given-names>
              </name>
              <name>
                <surname>Leverment</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Richards</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Seal</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Harris</surname>
                <given-names>GA</given-names>
              </name>
              <name>
                <surname>Cleland</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Dubowitz</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Collier</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>Milledge</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Stradling</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Morrell</surname>
                <given-names>MJ</given-names>
              </name>
            </person-group>
            <article-title>Temazepam at high altitude reduces periodic breathing without impairing next-day performance: a randomized cross-over double-blind study.</article-title>
            <source>J Sleep Res</source>
            <year>2006</year>
            <month>Dec</month>
            <volume>15</volume>
            <issue>4</issue>
            <fpage>445</fpage>
            <page-range>445-54</page-range>
            <pub-id pub-id-type="pmid">17118102</pub-id>
          </element-citation>
        </ref>
        <ref id="article-160552.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Roehrs</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Vogel</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Vogel</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Wittig</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Zorick</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Paxton</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Lamphere</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Roth</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>Dose effects of temazepam tablets on sleep.</article-title>
            <source>Drugs Exp Clin Res</source>
            <year>1986</year>
            <volume>12</volume>
            <issue>8</issue>
            <fpage>693</fpage>
            <page-range>693-9</page-range>
            <pub-id pub-id-type="pmid">2875858</pub-id>
          </element-citation>
        </ref>
        <ref id="article-160552.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mitler</surname>
                <given-names>MM</given-names>
              </name>
              <name>
                <surname>Browman</surname>
                <given-names>CP</given-names>
              </name>
              <name>
                <surname>Menn</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Gujavarty</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Timms</surname>
                <given-names>RM</given-names>
              </name>
            </person-group>
            <article-title>Nocturnal myoclonus: treatment efficacy of clonazepam and temazepam.</article-title>
            <source>Sleep</source>
            <year>1986</year>
            <volume>9</volume>
            <issue>3</issue>
            <fpage>385</fpage>
            <page-range>385-92</page-range>
            <pub-id pub-id-type="pmid">2876485</pub-id>
          </element-citation>
        </ref>
        <ref id="article-160552.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Amarasekera</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Temazepam as a premedicant in minor surgery.</article-title>
            <source>Anaesthesia</source>
            <year>1980</year>
            <month>Aug</month>
            <volume>35</volume>
            <issue>8</issue>
            <fpage>771</fpage>
            <page-range>771-4</page-range>
            <pub-id pub-id-type="pmid">6108729</pub-id>
          </element-citation>
        </ref>
        <ref id="article-160552.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Oelschl&#x000e4;ger</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>[Chemical and pharmacologic aspects of benzodiazepines].</article-title>
            <source>Schweiz Rundsch Med Prax</source>
            <year>1989</year>
            <month>Jul</month>
            <day>04</day>
            <volume>78</volume>
            <issue>27-28</issue>
            <fpage>766</fpage>
            <page-range>766-72</page-range>
            <pub-id pub-id-type="pmid">2570451</pub-id>
          </element-citation>
        </ref>
        <ref id="article-160552.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Welt</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Engelmann</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Renner</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Erhardt</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>M&#x000fc;ller</surname>
                <given-names>MB</given-names>
              </name>
              <name>
                <surname>Landgraf</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Holsboer</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Keck</surname>
                <given-names>ME</given-names>
              </name>
            </person-group>
            <article-title>Temazepam triggers the release of vasopressin into the rat hypothalamic paraventricular nucleus: novel insight into benzodiazepine action on hypothalamic-pituitary-adrenocortical system activity during stress.</article-title>
            <source>Neuropsychopharmacology</source>
            <year>2006</year>
            <month>Dec</month>
            <volume>31</volume>
            <issue>12</issue>
            <fpage>2573</fpage>
            <page-range>2573-9</page-range>
            <pub-id pub-id-type="pmid">16395302</pub-id>
          </element-citation>
        </ref>
        <ref id="article-160552.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ford</surname>
                <given-names>GA</given-names>
              </name>
              <name>
                <surname>Hoffman</surname>
                <given-names>BB</given-names>
              </name>
              <name>
                <surname>Blaschke</surname>
                <given-names>TF</given-names>
              </name>
            </person-group>
            <article-title>Effect of temazepam on blood pressure regulation in healthy elderly subjects.</article-title>
            <source>Br J Clin Pharmacol</source>
            <year>1990</year>
            <month>Jan</month>
            <volume>29</volume>
            <issue>1</issue>
            <fpage>61</fpage>
            <page-range>61-7</page-range>
            <pub-id pub-id-type="pmid">1967533</pub-id>
          </element-citation>
        </ref>
        <ref id="article-160552.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Goldschen-Ohm</surname>
                <given-names>MP</given-names>
              </name>
            </person-group>
            <article-title>Benzodiazepine Modulation of GABA<sub>A</sub> Receptors: A Mechanistic Perspective.</article-title>
            <source>Biomolecules</source>
            <year>2022</year>
            <month>Nov</month>
            <day>30</day>
            <volume>12</volume>
            <issue>12</issue>
            <pub-id pub-id-type="pmid">36551212</pub-id>
          </element-citation>
        </ref>
        <ref id="article-160552.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bianchi</surname>
                <given-names>MT</given-names>
              </name>
              <name>
                <surname>Botzolakis</surname>
                <given-names>EJ</given-names>
              </name>
              <name>
                <surname>Lagrange</surname>
                <given-names>AH</given-names>
              </name>
              <name>
                <surname>Macdonald</surname>
                <given-names>RL</given-names>
              </name>
            </person-group>
            <article-title>Benzodiazepine modulation of GABA(A) receptor opening frequency depends on activation context: a patch clamp and simulation study.</article-title>
            <source>Epilepsy Res</source>
            <year>2009</year>
            <month>Aug</month>
            <volume>85</volume>
            <issue>2-3</issue>
            <fpage>212</fpage>
            <page-range>212-20</page-range>
            <pub-id pub-id-type="pmid">19447010</pub-id>
          </element-citation>
        </ref>
        <ref id="article-160552.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Griffin</surname>
                <given-names>CE</given-names>
              </name>
              <name>
                <surname>Kaye</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Bueno</surname>
                <given-names>FR</given-names>
              </name>
              <name>
                <surname>Kaye</surname>
                <given-names>AD</given-names>
              </name>
            </person-group>
            <article-title>Benzodiazepine pharmacology and central nervous system-mediated effects.</article-title>
            <source>Ochsner J</source>
            <year>2013</year>
            <season>Summer</season>
            <volume>13</volume>
            <issue>2</issue>
            <fpage>214</fpage>
            <page-range>214-23</page-range>
            <pub-id pub-id-type="pmid">23789008</pub-id>
          </element-citation>
        </ref>
        <ref id="article-160552.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ochs</surname>
                <given-names>HR</given-names>
              </name>
              <name>
                <surname>Greenblatt</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>Heuer</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>Is temazepam an accumulating hypnotic?</article-title>
            <source>J Clin Pharmacol</source>
            <year>1984</year>
            <month>Jan</month>
            <volume>24</volume>
            <issue>1</issue>
            <fpage>58</fpage>
            <page-range>58-64</page-range>
            <pub-id pub-id-type="pmid">6142905</pub-id>
          </element-citation>
        </ref>
        <ref id="article-160552.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Divoll</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Greenblatt</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>Harmatz</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Shader</surname>
                <given-names>RI</given-names>
              </name>
            </person-group>
            <article-title>Effect of age and gender on disposition of temazepam.</article-title>
            <source>J Pharm Sci</source>
            <year>1981</year>
            <month>Oct</month>
            <volume>70</volume>
            <issue>10</issue>
            <fpage>1104</fpage>
            <page-range>1104-7</page-range>
            <pub-id pub-id-type="pmid">6117653</pub-id>
          </element-citation>
        </ref>
        <ref id="article-160552.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>E Eleraky</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>M Omar</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>A Mahmoud</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>A Abou-Taleb</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>Nanostructured Lipid Carriers to Mediate Brain Delivery of Temazepam: Design and In Vivo Study.</article-title>
            <source>Pharmaceutics</source>
            <year>2020</year>
            <month>May</month>
            <day>14</day>
            <volume>12</volume>
            <issue>5</issue>
            <pub-id pub-id-type="pmid">32422903</pub-id>
          </element-citation>
        </ref>
        <ref id="article-160552.r27">
          <label>27</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Marland</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Sarkar</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Leavitt</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>The urinary elimination profiles of diazepam and its metabolites, nordiazepam, temazepam, and oxazepam, in the equine after a 10-mg intramuscular dose.</article-title>
            <source>J Anal Toxicol</source>
            <year>1999</year>
            <season>Jan-Feb</season>
            <volume>23</volume>
            <issue>1</issue>
            <fpage>29</fpage>
            <page-range>29-34</page-range>
            <pub-id pub-id-type="pmid">10022206</pub-id>
          </element-citation>
        </ref>
        <ref id="article-160552.r28">
          <label>28</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Locniskar</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Greenblatt</surname>
                <given-names>DJ</given-names>
              </name>
            </person-group>
            <article-title>Oxidative versus conjugative biotransformation of temazepam.</article-title>
            <source>Biopharm Drug Dispos</source>
            <year>1990</year>
            <season>Aug-Sep</season>
            <volume>11</volume>
            <issue>6</issue>
            <fpage>499</fpage>
            <page-range>499-506</page-range>
            <pub-id pub-id-type="pmid">2207300</pub-id>
          </element-citation>
        </ref>
        <ref id="article-160552.r29">
          <label>29</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ochs</surname>
                <given-names>HR</given-names>
              </name>
              <name>
                <surname>Greenblatt</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>Verburg-Ochs</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Matlis</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Temazepam clearance unaltered in cirrhosis.</article-title>
            <source>Am J Gastroenterol</source>
            <year>1986</year>
            <month>Jan</month>
            <volume>81</volume>
            <issue>1</issue>
            <fpage>80</fpage>
            <page-range>80-4</page-range>
            <pub-id pub-id-type="pmid">2867675</pub-id>
          </element-citation>
        </ref>
        <ref id="article-160552.r30">
          <label>30</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>CHILDRESS</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>GLUCKMAN</surname>
                <given-names>MI</given-names>
              </name>
            </person-group>
            <article-title>1,4-BENZODIAZEPINES.</article-title>
            <source>J Pharm Sci</source>
            <year>1964</year>
            <month>Jun</month>
            <volume>53</volume>
            <fpage>577</fpage>
            <page-range>577-90</page-range>
            <pub-id pub-id-type="pmid">14198427</pub-id>
          </element-citation>
        </ref>
        <ref id="article-160552.r31">
          <label>31</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>English</surname>
                <given-names>BA</given-names>
              </name>
              <name>
                <surname>Dortch</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Ereshefsky</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Jhee</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Clinically significant psychotropic drug-drug interactions in the primary care setting.</article-title>
            <source>Curr Psychiatry Rep</source>
            <year>2012</year>
            <month>Aug</month>
            <volume>14</volume>
            <issue>4</issue>
            <fpage>376</fpage>
            <page-range>376-90</page-range>
            <pub-id pub-id-type="pmid">22707017</pub-id>
          </element-citation>
        </ref>
        <ref id="article-160552.r32">
          <label>32</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ghabrial</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Desmond</surname>
                <given-names>PV</given-names>
              </name>
              <name>
                <surname>Watson</surname>
                <given-names>KJ</given-names>
              </name>
              <name>
                <surname>Gijsbers</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Harman</surname>
                <given-names>PJ</given-names>
              </name>
              <name>
                <surname>Breen</surname>
                <given-names>KJ</given-names>
              </name>
              <name>
                <surname>Mashford</surname>
                <given-names>ML</given-names>
              </name>
            </person-group>
            <article-title>The effects of age and chronic liver disease on the elimination of temazepam.</article-title>
            <source>Eur J Clin Pharmacol</source>
            <year>1986</year>
            <volume>30</volume>
            <issue>1</issue>
            <fpage>93</fpage>
            <page-range>93-7</page-range>
            <pub-id pub-id-type="pmid">2872062</pub-id>
          </element-citation>
        </ref>
        <ref id="article-160552.r33">
          <label>33</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Andrade</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>The Practical Importance of Half-Life in Psychopharmacology.</article-title>
            <source>J Clin Psychiatry</source>
            <year>2022</year>
            <month>Jul</month>
            <day>25</day>
            <volume>83</volume>
            <issue>4</issue>
            <pub-id pub-id-type="pmid">35900254</pub-id>
          </element-citation>
        </ref>
        <ref id="article-160552.r34">
          <label>34</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lie</surname>
                <given-names>JD</given-names>
              </name>
              <name>
                <surname>Tu</surname>
                <given-names>KN</given-names>
              </name>
              <name>
                <surname>Shen</surname>
                <given-names>DD</given-names>
              </name>
              <name>
                <surname>Wong</surname>
                <given-names>BM</given-names>
              </name>
            </person-group>
            <article-title>Pharmacological Treatment of Insomnia.</article-title>
            <source>P T</source>
            <year>2015</year>
            <month>Nov</month>
            <volume>40</volume>
            <issue>11</issue>
            <fpage>759</fpage>
            <page-range>759-71</page-range>
            <pub-id pub-id-type="pmid">26609210</pub-id>
          </element-citation>
        </ref>
        <ref id="article-160552.r35">
          <label>35</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>McElnay</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Jones</surname>
                <given-names>ME</given-names>
              </name>
              <name>
                <surname>Alexander</surname>
                <given-names>B</given-names>
              </name>
            </person-group>
            <article-title>Temazepam (Restoril, Sandoz Pharmaceuticals).</article-title>
            <source>Drug Intell Clin Pharm</source>
            <year>1982</year>
            <month>Sep</month>
            <volume>16</volume>
            <issue>9</issue>
            <fpage>650</fpage>
            <page-range>650-6</page-range>
            <pub-id pub-id-type="pmid">6127197</pub-id>
          </element-citation>
        </ref>
        <ref id="article-160552.r36">
          <label>36</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Beary</surname>
                <given-names>MD</given-names>
              </name>
              <name>
                <surname>Lacey</surname>
                <given-names>JH</given-names>
              </name>
              <name>
                <surname>Crutchfield</surname>
                <given-names>MB</given-names>
              </name>
              <name>
                <surname>Bhat</surname>
                <given-names>AV</given-names>
              </name>
            </person-group>
            <article-title>Psycho-social stress, insomnia and temazepam: a sleep laboratory evaluation in a "general practice" sample.</article-title>
            <source>Psychopharmacology (Berl)</source>
            <year>1984</year>
            <volume>83</volume>
            <issue>1</issue>
            <fpage>17</fpage>
            <page-range>17-9</page-range>
            <pub-id pub-id-type="pmid">6146153</pub-id>
          </element-citation>
        </ref>
        <ref id="article-160552.r37">
          <label>37</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sateia</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Buysse</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>Krystal</surname>
                <given-names>AD</given-names>
              </name>
              <name>
                <surname>Neubauer</surname>
                <given-names>DN</given-names>
              </name>
              <name>
                <surname>Heald</surname>
                <given-names>JL</given-names>
              </name>
            </person-group>
            <article-title>Clinical Practice Guideline for the Pharmacologic Treatment of Chronic Insomnia in Adults: An American Academy of Sleep Medicine Clinical Practice Guideline.</article-title>
            <source>J Clin Sleep Med</source>
            <year>2017</year>
            <month>Feb</month>
            <day>15</day>
            <volume>13</volume>
            <issue>2</issue>
            <fpage>307</fpage>
            <page-range>307-349</page-range>
            <pub-id pub-id-type="pmid">27998379</pub-id>
          </element-citation>
        </ref>
        <ref id="article-160552.r38">
          <label>38</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Damen</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Visser</surname>
                <given-names>DH</given-names>
              </name>
              <name>
                <surname>Sie</surname>
                <given-names>SD</given-names>
              </name>
              <name>
                <surname>van Weissenbruch</surname>
                <given-names>MM</given-names>
              </name>
            </person-group>
            <article-title>Apparent Life-Threatening Event following Maternal Use of Temazepam during Labour.</article-title>
            <source>Case Rep Pediatr</source>
            <year>2014</year>
            <volume>2014</volume>
            <fpage>650605</fpage>
            <pub-id pub-id-type="pmid">25024861</pub-id>
          </element-citation>
        </ref>
        <ref id="article-160552.r39">
          <label>39</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Creeley</surname>
                <given-names>CE</given-names>
              </name>
              <name>
                <surname>Denton</surname>
                <given-names>LK</given-names>
              </name>
            </person-group>
            <article-title>Use of Prescribed Psychotropics during Pregnancy: A Systematic Review of Pregnancy, Neonatal, and Childhood Outcomes.</article-title>
            <source>Brain Sci</source>
            <year>2019</year>
            <month>Sep</month>
            <day>14</day>
            <volume>9</volume>
            <issue>9</issue>
            <pub-id pub-id-type="pmid">31540060</pub-id>
          </element-citation>
        </ref>
        <ref id="article-160552.r40">
          <label>40</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Brandlistuen</surname>
                <given-names>RE</given-names>
              </name>
              <name>
                <surname>Ystrom</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Hernandez-Diaz</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Skurtveit</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Selmer</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Handal</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Nordeng</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>Association of prenatal exposure to benzodiazepines and child internalizing problems: A sibling-controlled cohort study.</article-title>
            <source>PLoS One</source>
            <year>2017</year>
            <volume>12</volume>
            <issue>7</issue>
            <fpage>e0181042</fpage>
            <pub-id pub-id-type="pmid">28746341</pub-id>
          </element-citation>
        </ref>
        <ref id="article-160552.r41">
          <label>41</label>
          <element-citation publication-type="journal">
            <collab>By the 2023 American Geriatrics Society Beers Criteria&#x000ae; Update Expert Panel</collab>
            <article-title>American Geriatrics Society 2023 updated AGS Beers Criteria&#x000ae; for potentially inappropriate medication use in older adults.</article-title>
            <source>J Am Geriatr Soc</source>
            <year>2023</year>
            <month>Jul</month>
            <volume>71</volume>
            <issue>7</issue>
            <fpage>2052</fpage>
            <page-range>2052-2081</page-range>
            <pub-id pub-id-type="pmid">37139824</pub-id>
          </element-citation>
        </ref>
        <ref id="article-160552.r42">
          <label>42</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ruben</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Morrison</surname>
                <given-names>CL</given-names>
              </name>
            </person-group>
            <article-title>Temazepam misuse in a group of injecting drug users.</article-title>
            <source>Br J Addict</source>
            <year>1992</year>
            <month>Oct</month>
            <volume>87</volume>
            <issue>10</issue>
            <fpage>1387</fpage>
            <page-range>1387-92</page-range>
            <pub-id pub-id-type="pmid">1422104</pub-id>
          </element-citation>
        </ref>
        <ref id="article-160552.r43">
          <label>43</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Fowler</surname>
                <given-names>LK</given-names>
              </name>
            </person-group>
            <article-title>Post-marketing surveillance of Euhypnos (temazepam): a new hypnotic.</article-title>
            <source>J Int Med Res</source>
            <year>1980</year>
            <volume>8</volume>
            <issue>4</issue>
            <fpage>295</fpage>
            <page-range>295-9</page-range>
            <pub-id pub-id-type="pmid">6105982</pub-id>
          </element-citation>
        </ref>
        <ref id="article-160552.r44">
          <label>44</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pham Nguyen</surname>
                <given-names>TP</given-names>
              </name>
              <name>
                <surname>Soprano</surname>
                <given-names>SE</given-names>
              </name>
              <name>
                <surname>Hennessy</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Brensinger</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Bilker</surname>
                <given-names>WB</given-names>
              </name>
              <name>
                <surname>Miano</surname>
                <given-names>TA</given-names>
              </name>
              <name>
                <surname>Acton</surname>
                <given-names>EK</given-names>
              </name>
              <name>
                <surname>Horn</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Chung</surname>
                <given-names>SP</given-names>
              </name>
              <name>
                <surname>Dublin</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Oslin</surname>
                <given-names>DW</given-names>
              </name>
              <name>
                <surname>Wiebe</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>Leonard</surname>
                <given-names>CE</given-names>
              </name>
            </person-group>
            <article-title>Population-based signals of benzodiazepine drug interactions associated with unintentional traumatic injury.</article-title>
            <source>J Psychiatr Res</source>
            <year>2022</year>
            <month>Jul</month>
            <volume>151</volume>
            <fpage>299</fpage>
            <page-range>299-303</page-range>
            <pub-id pub-id-type="pmid">35526445</pub-id>
          </element-citation>
        </ref>
        <ref id="article-160552.r45">
          <label>45</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Geulayov</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Ferrey</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Casey</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Wells</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Fuller</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Bankhead</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Gunnell</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Clements</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Kapur</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Ness</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Waters</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Hawton</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Relative toxicity of benzodiazepines and hypnotics commonly used for self-poisoning: An epidemiological study of fatal toxicity and case fatality.</article-title>
            <source>J Psychopharmacol</source>
            <year>2018</year>
            <month>Jun</month>
            <volume>32</volume>
            <issue>6</issue>
            <fpage>654</fpage>
            <page-range>654-662</page-range>
            <pub-id pub-id-type="pmid">29442611</pub-id>
          </element-citation>
        </ref>
        <ref id="article-160552.r46">
          <label>46</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tiplady</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Hiroz</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Holmes</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Drummond</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Errors in performance testing: a comparison of ethanol and temazepam.</article-title>
            <source>J Psychopharmacol</source>
            <year>2003</year>
            <month>Mar</month>
            <volume>17</volume>
            <issue>1</issue>
            <fpage>41</fpage>
            <page-range>41-9</page-range>
            <pub-id pub-id-type="pmid">12680738</pub-id>
          </element-citation>
        </ref>
        <ref id="article-160552.r47">
          <label>47</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Vadiei</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Bhattacharjee</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Concurrent Opioid and Benzodiazepine Utilization Patterns and Predictors Among Community-Dwelling Adults in the United States.</article-title>
            <source>Psychiatr Serv</source>
            <year>2020</year>
            <month>Oct</month>
            <day>01</day>
            <volume>71</volume>
            <issue>10</issue>
            <fpage>1011</fpage>
            <page-range>1011-1019</page-range>
            <pub-id pub-id-type="pmid">32517642</pub-id>
          </element-citation>
        </ref>
        <ref id="article-160552.r48">
          <label>48</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lader</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Anxiolytic drugs: dependence, addiction and abuse.</article-title>
            <source>Eur Neuropsychopharmacol</source>
            <year>1994</year>
            <month>Jun</month>
            <volume>4</volume>
            <issue>2</issue>
            <fpage>85</fpage>
            <page-range>85-91</page-range>
            <pub-id pub-id-type="pmid">7919947</pub-id>
          </element-citation>
        </ref>
        <ref id="article-160552.r49">
          <label>49</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dobbin</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Martyres</surname>
                <given-names>RF</given-names>
              </name>
              <name>
                <surname>Clode</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Champion De Crespigny</surname>
                <given-names>FE</given-names>
              </name>
            </person-group>
            <article-title>Association of benzodiazepine injection with the prescription of temazepam capsules.</article-title>
            <source>Drug Alcohol Rev</source>
            <year>2003</year>
            <month>Jun</month>
            <volume>22</volume>
            <issue>2</issue>
            <fpage>153</fpage>
            <page-range>153-7</page-range>
            <pub-id pub-id-type="pmid">12850901</pub-id>
          </element-citation>
        </ref>
        <ref id="article-160552.r50">
          <label>50</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Scott</surname>
                <given-names>RN</given-names>
              </name>
              <name>
                <surname>Going</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Woodburn</surname>
                <given-names>KR</given-names>
              </name>
              <name>
                <surname>Gilmour</surname>
                <given-names>DG</given-names>
              </name>
              <name>
                <surname>Reid</surname>
                <given-names>DB</given-names>
              </name>
              <name>
                <surname>Leiberman</surname>
                <given-names>DP</given-names>
              </name>
              <name>
                <surname>Maraj</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Pollock</surname>
                <given-names>JG</given-names>
              </name>
            </person-group>
            <article-title>Intra-arterial temazepam.</article-title>
            <source>BMJ</source>
            <year>1992</year>
            <month>Jun</month>
            <day>20</day>
            <volume>304</volume>
            <issue>6842</issue>
            <fpage>1630</fpage>
            <pub-id pub-id-type="pmid">1628096</pub-id>
          </element-citation>
        </ref>
        <ref id="article-160552.r51">
          <label>51</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Forsyth</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Farquhar</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Gemmell</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Shewan</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Davies</surname>
                <given-names>JB</given-names>
              </name>
            </person-group>
            <article-title>The dual use of opioids and temazepam by drug injectors in Glasgow (Scotland).</article-title>
            <source>Drug Alcohol Depend</source>
            <year>1993</year>
            <month>May</month>
            <volume>32</volume>
            <issue>3</issue>
            <fpage>277</fpage>
            <page-range>277-80</page-range>
            <pub-id pub-id-type="pmid">8348877</pub-id>
          </element-citation>
        </ref>
        <ref id="article-160552.r52">
          <label>52</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Miller</surname>
                <given-names>LG</given-names>
              </name>
              <name>
                <surname>Greenblatt</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>Roy</surname>
                <given-names>RB</given-names>
              </name>
              <name>
                <surname>Summer</surname>
                <given-names>WR</given-names>
              </name>
              <name>
                <surname>Shader</surname>
                <given-names>RI</given-names>
              </name>
            </person-group>
            <article-title>Chronic benzodiazepine administration. II. Discontinuation syndrome is associated with upregulation of gamma-aminobutyric acidA receptor complex binding and function.</article-title>
            <source>J Pharmacol Exp Ther</source>
            <year>1988</year>
            <month>Jul</month>
            <volume>246</volume>
            <issue>1</issue>
            <fpage>177</fpage>
            <page-range>177-82</page-range>
            <pub-id pub-id-type="pmid">2455789</pub-id>
          </element-citation>
        </ref>
        <ref id="article-160552.r53">
          <label>53</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kales</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Bixler</surname>
                <given-names>EO</given-names>
              </name>
              <name>
                <surname>Soldatos</surname>
                <given-names>CR</given-names>
              </name>
              <name>
                <surname>Vela-Bueno</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Jacoby</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Kales</surname>
                <given-names>JD</given-names>
              </name>
            </person-group>
            <article-title>Quazepam and temazepam: effects of short- and intermediate-term use and withdrawal.</article-title>
            <source>Clin Pharmacol Ther</source>
            <year>1986</year>
            <month>Mar</month>
            <volume>39</volume>
            <issue>3</issue>
            <fpage>345</fpage>
            <page-range>345-52</page-range>
            <pub-id pub-id-type="pmid">2868823</pub-id>
          </element-citation>
        </ref>
        <ref id="article-160552.r54">
          <label>54</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kales</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Manfredi</surname>
                <given-names>RL</given-names>
              </name>
              <name>
                <surname>Vgontzas</surname>
                <given-names>AN</given-names>
              </name>
              <name>
                <surname>Bixler</surname>
                <given-names>EO</given-names>
              </name>
              <name>
                <surname>Vela-Bueno</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Fee</surname>
                <given-names>EC</given-names>
              </name>
            </person-group>
            <article-title>Rebound insomnia after only brief and intermittent use of rapidly eliminated benzodiazepines.</article-title>
            <source>Clin Pharmacol Ther</source>
            <year>1991</year>
            <month>Apr</month>
            <volume>49</volume>
            <issue>4</issue>
            <fpage>468</fpage>
            <page-range>468-76</page-range>
            <pub-id pub-id-type="pmid">2015735</pub-id>
          </element-citation>
        </ref>
        <ref id="article-160552.r55">
          <label>55</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Edinoff</surname>
                <given-names>AN</given-names>
              </name>
              <name>
                <surname>Nix</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>Hollier</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Sagrera</surname>
                <given-names>CE</given-names>
              </name>
              <name>
                <surname>Delacroix</surname>
                <given-names>BM</given-names>
              </name>
              <name>
                <surname>Abubakar</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Cornett</surname>
                <given-names>EM</given-names>
              </name>
              <name>
                <surname>Kaye</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Kaye</surname>
                <given-names>AD</given-names>
              </name>
            </person-group>
            <article-title>Benzodiazepines: Uses, Dangers, and Clinical Considerations.</article-title>
            <source>Neurol Int</source>
            <year>2021</year>
            <month>Nov</month>
            <day>10</day>
            <volume>13</volume>
            <issue>4</issue>
            <fpage>594</fpage>
            <page-range>594-607</page-range>
            <pub-id pub-id-type="pmid">34842811</pub-id>
          </element-citation>
        </ref>
        <ref id="article-160552.r56">
          <label>56</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lader</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Benzodiazepine harm: how can it be reduced?</article-title>
            <source>Br J Clin Pharmacol</source>
            <year>2014</year>
            <month>Feb</month>
            <volume>77</volume>
            <issue>2</issue>
            <fpage>295</fpage>
            <page-range>295-301</page-range>
            <pub-id pub-id-type="pmid">22882333</pub-id>
          </element-citation>
        </ref>
        <ref id="article-160552.r57">
          <label>57</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Calcaterra</surname>
                <given-names>SL</given-names>
              </name>
              <name>
                <surname>Butler</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Olson</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Blum</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>The Impact of a PDMP-EHR Data Integration Combined With Clinical Decision Support on Opioid and Benzodiazepine Prescribing Across Clinicians in a Metropolitan Area.</article-title>
            <source>J Addict Med</source>
            <string-date>2022 May-Jun 01</string-date>
            <volume>16</volume>
            <issue>3</issue>
            <fpage>324</fpage>
            <page-range>324-332</page-range>
            <pub-id pub-id-type="pmid">34392255</pub-id>
          </element-citation>
        </ref>
        <ref id="article-160552.r58">
          <label>58</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Fung</surname>
                <given-names>CH</given-names>
              </name>
              <name>
                <surname>Martin</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Dzierzewski</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Jouldjian</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Josephson</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Park</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Alessi</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Prevalence and symptoms of occult sleep disordered breathing among older veterans with insomnia.</article-title>
            <source>J Clin Sleep Med</source>
            <year>2013</year>
            <month>Nov</month>
            <day>15</day>
            <volume>9</volume>
            <issue>11</issue>
            <fpage>1173</fpage>
            <page-range>1173-8</page-range>
            <pub-id pub-id-type="pmid">24235899</pub-id>
          </element-citation>
        </ref>
        <ref id="article-160552.r59">
          <label>59</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rundo</surname>
                <given-names>JV</given-names>
              </name>
              <name>
                <surname>Downey</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Polysomnography.</article-title>
            <source>Handb Clin Neurol</source>
            <year>2019</year>
            <volume>160</volume>
            <fpage>381</fpage>
            <page-range>381-392</page-range>
            <pub-id pub-id-type="pmid">31277862</pub-id>
          </element-citation>
        </ref>
        <ref id="article-160552.r60">
          <label>60</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Irwin</surname>
                <given-names>MR</given-names>
              </name>
              <name>
                <surname>Carrillo</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Sadeghi</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Bjurstrom</surname>
                <given-names>MF</given-names>
              </name>
              <name>
                <surname>Breen</surname>
                <given-names>EC</given-names>
              </name>
              <name>
                <surname>Olmstead</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Prevention of Incident and Recurrent Major Depression in Older Adults With Insomnia: A Randomized Clinical Trial.</article-title>
            <source>JAMA Psychiatry</source>
            <year>2022</year>
            <month>Jan</month>
            <day>01</day>
            <volume>79</volume>
            <issue>1</issue>
            <fpage>33</fpage>
            <page-range>33-41</page-range>
            <pub-id pub-id-type="pmid">34817561</pub-id>
          </element-citation>
        </ref>
        <ref id="article-160552.r61">
          <label>61</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Michaud</surname>
                <given-names>AL</given-names>
              </name>
              <name>
                <surname>Zhou</surname>
                <given-names>ES</given-names>
              </name>
              <name>
                <surname>Chang</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Recklitis</surname>
                <given-names>CJ</given-names>
              </name>
            </person-group>
            <article-title>Validation of the Insomnia Severity Index (ISI) for identifying insomnia in young adult cancer survivors: comparison with a structured clinical diagnostic interview of the DSM-5 (SCID-5).</article-title>
            <source>Sleep Med</source>
            <year>2021</year>
            <month>May</month>
            <volume>81</volume>
            <fpage>80</fpage>
            <page-range>80-85</page-range>
            <pub-id pub-id-type="pmid">33640841</pub-id>
          </element-citation>
        </ref>
        <ref id="article-160552.r62">
          <label>62</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Morin</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Belleville</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>B&#x000e9;langer</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Ivers</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>The Insomnia Severity Index: psychometric indicators to detect insomnia cases and evaluate treatment response.</article-title>
            <source>Sleep</source>
            <year>2011</year>
            <month>May</month>
            <day>01</day>
            <volume>34</volume>
            <issue>5</issue>
            <fpage>601</fpage>
            <page-range>601-8</page-range>
            <pub-id pub-id-type="pmid">21532953</pub-id>
          </element-citation>
        </ref>
        <ref id="article-160552.r63">
          <label>63</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Buckley</surname>
                <given-names>NA</given-names>
              </name>
              <name>
                <surname>Dawson</surname>
                <given-names>AH</given-names>
              </name>
              <name>
                <surname>Whyte</surname>
                <given-names>IM</given-names>
              </name>
              <name>
                <surname>O'Connell</surname>
                <given-names>DL</given-names>
              </name>
            </person-group>
            <article-title>Relative toxicity of benzodiazepines in overdose.</article-title>
            <source>BMJ</source>
            <year>1995</year>
            <month>Jan</month>
            <day>28</day>
            <volume>310</volume>
            <issue>6974</issue>
            <fpage>219</fpage>
            <page-range>219-21</page-range>
            <pub-id pub-id-type="pmid">7866122</pub-id>
          </element-citation>
        </ref>
        <ref id="article-160552.r64">
          <label>64</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Park</surname>
                <given-names>TW</given-names>
              </name>
              <name>
                <surname>Saitz</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Ganoczy</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Ilgen</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Bohnert</surname>
                <given-names>AS</given-names>
              </name>
            </person-group>
            <article-title>Benzodiazepine prescribing patterns and deaths from drug overdose among US veterans receiving opioid analgesics: case-cohort study.</article-title>
            <source>BMJ</source>
            <year>2015</year>
            <month>Jun</month>
            <day>10</day>
            <volume>350</volume>
            <fpage>h2698</fpage>
            <pub-id pub-id-type="pmid">26063215</pub-id>
          </element-citation>
        </ref>
        <ref id="article-160552.r65">
          <label>65</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Farkas</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Kostic</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Huang</surname>
                <given-names>CC</given-names>
              </name>
              <name>
                <surname>Gummin</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Poison center consultation reduces hospital length of stay.</article-title>
            <source>Clin Toxicol (Phila)</source>
            <year>2022</year>
            <month>Jul</month>
            <volume>60</volume>
            <issue>7</issue>
            <fpage>863</fpage>
            <page-range>863-868</page-range>
            <pub-id pub-id-type="pmid">35261300</pub-id>
          </element-citation>
        </ref>
        <ref id="article-160552.r66">
          <label>66</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Kang</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Galuska</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Ghassemzadeh</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <chapter-title>Benzodiazepine Toxicity</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2023</year>
            <month>6</month>
            <day>26</day>
            <pub-id pub-id-type="pmid">29489152</pub-id>
          </element-citation>
        </ref>
        <ref id="article-160552.r67">
          <label>67</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Harvey</surname>
                <given-names>CJ</given-names>
              </name>
              <name>
                <surname>Gehrman</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Espie</surname>
                <given-names>CA</given-names>
              </name>
            </person-group>
            <article-title>Who is predisposed to insomnia: a review of familial aggregation, stress-reactivity, personality and coping style.</article-title>
            <source>Sleep Med Rev</source>
            <year>2014</year>
            <month>Jun</month>
            <volume>18</volume>
            <issue>3</issue>
            <fpage>237</fpage>
            <page-range>237-47</page-range>
            <pub-id pub-id-type="pmid">24480386</pub-id>
          </element-citation>
        </ref>
        <ref id="article-160552.r68">
          <label>68</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Jarrin</surname>
                <given-names>DC</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>IY</given-names>
              </name>
              <name>
                <surname>Ivers</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Morin</surname>
                <given-names>CM</given-names>
              </name>
            </person-group>
            <article-title>The role of vulnerability in stress-related insomnia, social support and coping styles on incidence and persistence of insomnia.</article-title>
            <source>J Sleep Res</source>
            <year>2014</year>
            <month>Dec</month>
            <volume>23</volume>
            <issue>6</issue>
            <fpage>681</fpage>
            <page-range>681-688</page-range>
            <pub-id pub-id-type="pmid">25040302</pub-id>
          </element-citation>
        </ref>
        <ref id="article-160552.r69">
          <label>69</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cortese</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Epigenetics of Sleep Disorders: An Emerging Field in Diagnosis and Therapeutics.</article-title>
            <source>Diagnostics (Basel)</source>
            <year>2021</year>
            <month>May</month>
            <day>10</day>
            <volume>11</volume>
            <issue>5</issue>
            <pub-id pub-id-type="pmid">34068472</pub-id>
          </element-citation>
        </ref>
        <ref id="article-160552.r70">
          <label>70</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Palagini</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Biber</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Riemann</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>The genetics of insomnia--evidence for epigenetic mechanisms?</article-title>
            <source>Sleep Med Rev</source>
            <year>2014</year>
            <month>Jun</month>
            <volume>18</volume>
            <issue>3</issue>
            <fpage>225</fpage>
            <page-range>225-35</page-range>
            <pub-id pub-id-type="pmid">23932332</pub-id>
          </element-citation>
        </ref>
        <ref id="article-160552.r71">
          <label>71</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Brian&#x000e7;on-Marjollet</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Weiszenstein</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Henri</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Thomas</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Godin-Ribuot</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Polak</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>The impact of sleep disorders on glucose metabolism: endocrine and molecular mechanisms.</article-title>
            <source>Diabetol Metab Syndr</source>
            <year>2015</year>
            <volume>7</volume>
            <fpage>25</fpage>
            <pub-id pub-id-type="pmid">25834642</pub-id>
          </element-citation>
        </ref>
        <ref id="article-160552.r72">
          <label>72</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Han</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>WZ</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>YC</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Zeng</surname>
                <given-names>ZQ</given-names>
              </name>
            </person-group>
            <article-title>Sleep and hypertension.</article-title>
            <source>Sleep Breath</source>
            <year>2020</year>
            <month>Mar</month>
            <volume>24</volume>
            <issue>1</issue>
            <fpage>351</fpage>
            <page-range>351-356</page-range>
            <pub-id pub-id-type="pmid">31402441</pub-id>
          </element-citation>
        </ref>
        <ref id="article-160552.r73">
          <label>73</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Medic</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Wille</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Hemels</surname>
                <given-names>ME</given-names>
              </name>
            </person-group>
            <article-title>Short- and long-term health consequences of sleep disruption.</article-title>
            <source>Nat Sci Sleep</source>
            <year>2017</year>
            <volume>9</volume>
            <fpage>151</fpage>
            <page-range>151-161</page-range>
            <pub-id pub-id-type="pmid">28579842</pub-id>
          </element-citation>
        </ref>
        <ref id="article-160552.r74">
          <label>74</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Caruso</surname>
                <given-names>CC</given-names>
              </name>
            </person-group>
            <article-title>Negative impacts of shiftwork and long work hours.</article-title>
            <source>Rehabil Nurs</source>
            <year>2014</year>
            <season>Jan-Feb</season>
            <volume>39</volume>
            <issue>1</issue>
            <fpage>16</fpage>
            <page-range>16-25</page-range>
            <pub-id pub-id-type="pmid">23780784</pub-id>
          </element-citation>
        </ref>
        <ref id="article-160552.r75">
          <label>75</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Walker</surname>
                <given-names>MP</given-names>
              </name>
              <name>
                <surname>van der Helm</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>Overnight therapy? The role of sleep in emotional brain processing.</article-title>
            <source>Psychol Bull</source>
            <year>2009</year>
            <month>Sep</month>
            <volume>135</volume>
            <issue>5</issue>
            <fpage>731</fpage>
            <page-range>731-48</page-range>
            <pub-id pub-id-type="pmid">19702380</pub-id>
          </element-citation>
        </ref>
        <ref id="article-160552.r76">
          <label>76</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Amellal</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Binck</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Frossard</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Ilien</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Landry</surname>
                <given-names>Y</given-names>
              </name>
            </person-group>
            <article-title>Sodium-potassium ATPase inhibition potentiates compound 48/80-induced histamine secretion from mast cells.</article-title>
            <source>Br J Pharmacol</source>
            <year>1984</year>
            <month>Jun</month>
            <volume>82</volume>
            <issue>2</issue>
            <fpage>423</fpage>
            <page-range>423-30</page-range>
            <pub-id pub-id-type="pmid">6203594</pub-id>
          </element-citation>
        </ref>
        <ref id="article-160552.r77">
          <label>77</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dunleavy</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Tonon</surname>
                <given-names>AC</given-names>
              </name>
              <name>
                <surname>Chua</surname>
                <given-names>AP</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Cheung</surname>
                <given-names>KL</given-names>
              </name>
              <name>
                <surname>Thach</surname>
                <given-names>TQ</given-names>
              </name>
              <name>
                <surname>Rykov</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Soh</surname>
                <given-names>CK</given-names>
              </name>
              <name>
                <surname>Christopoulos</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>de Vries</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Car</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>A Multifactorial Approach to Sleep and Its Association with Health-Related Quality of Life in a Multiethnic Asian Working Population: A Cross-Sectional Analysis.</article-title>
            <source>Int J Environ Res Public Health</source>
            <year>2019</year>
            <month>Oct</month>
            <day>28</day>
            <volume>16</volume>
            <issue>21</issue>
            <pub-id pub-id-type="pmid">31661849</pub-id>
          </element-citation>
        </ref>
        <ref id="article-160552.r78">
          <label>78</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Roth</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>Insomnia: definition, prevalence, etiology, and consequences.</article-title>
            <source>J Clin Sleep Med</source>
            <year>2007</year>
            <month>Aug</month>
            <day>15</day>
            <volume>3</volume>
            <issue>5 Suppl</issue>
            <fpage>S7</fpage>
            <page-range>S7-10</page-range>
            <pub-id pub-id-type="pmid">17824495</pub-id>
          </element-citation>
        </ref>
        <ref id="article-160552.r79">
          <label>79</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Green</surname>
                <given-names>ME</given-names>
              </name>
              <name>
                <surname>Bernet</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Cheung</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Thyroid Dysfunction and Sleep Disorders.</article-title>
            <source>Front Endocrinol (Lausanne)</source>
            <year>2021</year>
            <volume>12</volume>
            <fpage>725829</fpage>
            <pub-id pub-id-type="pmid">34504473</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
